Medicinal product to obtain a powder aerosol

 

(57) Abstract:

The tool contains, wt%: the active substance is from 0.01 to 5 and liquefied petroleum working gas 1,1,1,2,3,3,3-Heptafluoropropane rest. The active substance is selected from the group comprising substances --mimetic, anticholinergic, antiallergicheskie and antagonistic against platelet-activating factor activity. The tool may further comprise a lower alkane in the amount of 4 - 60 wt.% and at least one surfactant in an amount of 0.01 - 10 wt.%. The tool is used for obtaining the powder spray is an effective and environmentally friendly. 2 C.p. f-crystals, 7 other

The invention relates to aerosols for medical purposes, in particular medicinal product to obtain a powder aerosol.

Known drug to obtain a powder aerosol containing micronized active substance selected from the group comprising substances-mimetic, anticholinergic, anti-allergic and antagonistic against platelet-activating factor activity, steroids, and combinations thereof, and at least one liquefied harperonevideo chlorine partially fluorinated hydrocarbons show a negative effect on the earth's atmosphere, in connection with what is known cannot be considered environmentally friendly.

The objective of the invention is the development of a medicinal product to obtain a powder aerosol, which is not only environmentally friendly, but also on all performance is not inferior to the famous.

The problem is solved by the proposed medicinal product to obtain a powder aerosol containing micronized active substance selected from the group comprising substances-mimetic, anticholinergic, anti-allergic and antagonistic against platelet-activating factor activity, steroids, and combinations thereof, and at least one liquefied working gas, due to the fact that as a liquefied hydrocarbon propellant gas it contains 1,1,1,2,3,3,3-Heptafluoropropane in the following ratio, wt.%:

The active substance of this group is 0.01 - 5

1,1,1,2,3,3,3-heptabromo - Rest

The tool may further comprise a lower alkane in the amount of 4 - 60 wt. %. In addition, the tool may contain at least one surfactant in an amount of 0.01 - 10 wt.%.

Appreciate the interest data refer to the weight of the tool.

Formula N 1

Oxitropium-bromide - 0,10

1,1,1,2,3,3,3,-Heptafluoropropane - 95,89

Pentane - 4,00

Soy lecithin is from 0.01 to 100.00

Formula N 2

Fenoterol - 0,3

1,1,1,2,3,3,3,-Heptafluoropropane - 70,0

Bhutan - 19,6

Pentane - 10,0

Soy lecithin - 0,1 - 100,0

Formula N 3

Ipratropium-bromide - 0,1

1,1,1,2,3,3,3,-Heptafluoropropane - 59,8

Propane - 20,0

Bhutan - 20,0

Soy lecithin - 0,1 - 100,0

Recipe # 4

Fenoterol - 0,3

1,1,1,2,3,3,3,-Heptafluoropropane - 10,0

Propane - 20,00

Bhutan - 10,0

Soy lecithin - 0,1 - 100,0

Formula N 5

The salbutamol - 0,3

1,1,1,2,3,3,3-Heptafluoropropane - 60,0

Bhutan is 19.5

Pentane - 20,0

Arbitarily ester of oleic acid - 20,0

Soy lecithin is 0.2 - 100,0

Recipe N 6

Protropin-bromide - 0,1

1,1,1,2,3,3,3-Heptafluoropropane - 54,0

Bhutan is 30.5

Propane and 15.3

Arbitarily ester of oleic acid - 20,0

Soy lecithin - 0,1 - 100,0

Recipe # 7

Cromoglycate disodium - 1,5

Tween-20 (politicsservicesemail) - 0,1

1,1,1,2,3,3,3-Heptafluoropropane - 98,4 - 100,0 p

1 1. Medicinal product to obtain a powder aerosol containing micronized active substance, selected from the group vcloud platelet factor activity, steroids and combinations thereof, and liquefied petroleum working gas, characterized in that as a liquefied hydrocarbon propellant gas it contains 1,1,1,2,3,3,3-Heptafluoropropane in the following ratio, wt.%: 3 Active substance from the specified group7 0,01 - 5,0 3 1,1,1,2,3,3,3-Heptafluoropropane 7 Else 2 2. Drug under item 1, characterized in that it further comprises a lower alkane in the amount of 4 - 60 wt.%. 2 3. Drug under item 1, characterized in that it additionally contains at least one surfactant in an amount of 0.01 - 10 wt.%.

 

Same patents:

The invention relates to medicine, namely to the drugs used for treatment of bronchial asthma

The invention relates to the composition of the plasma substitute, which as colloidal composite part contains ester starch

The invention relates to the field of medical industry, and in particular to methods of obtaining dispersible in water preparations of beta-carotene

Eye ointment // 2082434
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment of traumatic keratitis, chemical burns, conjunctivitis, corneal, and especially when wound infection

The invention relates to a method of stabilizing 4-ethyl-2-hydroxyimino-5-nitro-3-hexanamide formula [1], in particular //-/E/-4-ethyl-2-/(E)-hydroxyimino/-5-Ni - tro-3-hexanamide or its salts, acceptable as medicines or medicines containing as active ingredient the specified connection [1]

CH3--ONH2..

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to producing a medicinal preparation with analgesic, antipyretic and anti-inflammatory effect. The preparation is made as a tablet comprising a core containing ibuprofen as an active substance wherein a core is covered by envelope masking taste of the preparation. Core comprises potato starch and calcium stearate as special additives, and envelope comprises sugar, magnesium basic carbonate, polyvinylpyrrolidone, aerosil, talc, titanium dioxide, gelatin, vanillin, dye acid red and bee wax. Invention provides the necessary quality and necessary therapeutic effect of tablets due to rapid release of active substance from the tablet core wherein the core decomposition is 7-8 min and that in dissolving and 92-94% of active component transfers to medium in 45 min.

EFFECT: improved method for preparing, improved and valuable medicinal and pharmaceutical properties of preparation.

4 cl, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with delivering a stable biologically active compound for a subject including glass particles that contain the mentioned biologically active compound at their diameter ranged 0.1-100 mcm and suspended in liquid that includes, at least, one biocompatible perfluorocarbon where these mentioned particles are not dissolved. The innovation enables to create completely stable compositions being ready for injections.

EFFECT: higher efficiency.

11 cl, 2 dwg, 11 ex

FIELD: neurological diseases.

SUBSTANCE: composition contains therapeutically effective amount of anticonvulsant agent dissolved or dispersed in aqueous carrier containing 10-80 vol % aliphatic alcohol, 10-80 vol % ethylene glycol, and 0.1-5 vol % bile acid salt or lecithin. Indicated carrier ensures increased access of anticonvulsant agent (such as benzodiazepin, in particular diazepam, clonazepam, phoenitoin, mephoenitoin, ethotoin, phenobarbital, carbamazepin, ethosuccinamide, valproic acid, gabapentine, trimethadion, lamotrigin) into blood and rapid pharmacological response when using nasal administration.

EFFECT: accelerated anticonvulsant effect.

11 cl, 9 dwg, 10 tbl, 13 ex

FIELD: pharmaceutical industry and cosmetics.

SUBSTANCE: composition contains, wt %: biologically active component isolated from medicinal leech or its parts 0.01-6.0, menthol 0.15-0.25, aqueous-alcoholic extract of horse-chestnut fruitage 8-10, camphor 0.15-0.30, ethoxydiglycol 3-5, polyethyleneglycol 1500, 0.8-1.2, emulgin B2, 0.8-1,2, Carbomer 0.6-0.8, triethanolamine 0.6-0.8, methylparben 0.25-0.35, Bronopol 0.04-0.06, butyloxyanisol 0.06-0.08, and water to 100%. Composition is made in the form of gel and provides antithrombic and analeptic effects on skin and hypodermic tissues, enhances antiinflammatory action, favors deep penetration of active components through skin, strengthens venous vessel walls, improves microcirculation of blood, and accelerated restoration of vascular wall tone.

EFFECT: expanded therapeutical possibilities.

2 cl, 2 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: therapeutical composition contains sea-buckthorn extract, biologically active component isolated from medicinal leech or its parts, aqueous-alcoholic extract of horse-chestnut fruitage, methyluracyl, anestesin, Carbomer, triethanolamine, methylparben, Bronopol, butyloxyanisol, and water. Utilization of the composition promotes activation of metabolic processes in rectum mucosa, anesthetizes and accelerates microcirculation of blood, produces antithrombic and thrombolytic effects, which results in rapid achievement of stable therapeutical effect in suppressing hemorrhoids and inflammatory process in rectum.

EFFECT: enhanced therapeutical efficiency.

2 tbl

FIELD: medicine, pharmaceutical technology.

SUBSTANCE: invention relates to a method for preparing medicinal suspension aerosol compositions based on hydrofluoroalkanes comprising parmitic and stearic acid calcium, magnesium and zinc salts additionally as solid agents improving stability of suspension, mechanical effect of a dosing valve, dosing precision and chemical stability of active substance.

EFFECT: improved and valuable properties of compositions.

8 cl, 6 ex

FIELD: pharmaceutical industry and infection diseases.

SUBSTANCE: invention relates to pharmaceutical compositions for treatment and prevention of bacterial infections. Pharmaceutical composition comprises filler containing (a) amphipathic oil, which is dispersible in water and insoluble in ethanol, (b) microcrystalline wax, (c) pharmaceutically acceptable non-aqueous carrier, and further contains antibacterial agent stably dispersed in filler in antibacterial efficient amount. Composition is suitable to be introduced by means of intramammar infusion to a milk-producing animal for treatment or prevention of mastitis or another udder disease, or for to be aurally introduced for treatment and/or prevention of infectional year disease. Industrially-made article comprises container or delivering device having oxygen-permeable wall or accommodating indicated composition. Method of treatment or prevention of bacterial disease in a subject comprises introducing indicated composition into liquid-containing subject's organ through natural outside opening of this organ, composition being dispersed in mentioned liquid during the introduction.

EFFECT: lowered interphase tension in composition, which allows antibacterial agent contained in composition to be quickly dispersed resulting in a rapid achievement of effective levels of drug on infection-damaged site.

18 cl, 7 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention concerns new compositions containing: (a) GLP-1 compound selected out of a group including GLP-1 compounds represented in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14; and (b) transport medium selected out of a group including transport media 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 and 56. These compositions enable easy GLP-1 compound absorption by peroral administration, thus allowing peroral administration of GLP-1 compound, omitting multiple injections.

EFFECT: improved efficiency of the composition and treatment method.

18 cl, 9 ex, 4 tbl, 22 dwg

FIELD: medicine.

SUBSTANCE: methods includes, for instance, gel compositions of prolonged action, which can be injected in desired location and which can ensure controlled release of medical medication during long time period. Compositions include biocompatible polymer, biocompatible solvent, having low solubility in water, forming viscous gel with polymer and limiting water absorption by implant, as well as medication.

EFFECT: systemic or local introduction of medication to patient.

42 cl, 25 ex, 13 tbl, 21 dwg

Adjuvant // 2355423

FIELD: medicine; virology.

SUBSTANCE: claimed is application of birch bark extract as adjuvant. Invention can be used in veterinary and medicine.

EFFECT: birch bark extract increases immunogenity of target antigen in combined introduction.

3 cl, 4 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves introducing particles into patient's respiratory tract from a reservoir containing some mass of the particles having filling density of 0.4 g/cm3. At least 50% by mass of particles containing in the reservoir are delivered to pulmonary system of a patient. At least 75% of particles have small particles fraction which size is smaller than 6.8 mcm. The particles are capable of carrying agents like biologically active agents.

EFFECT: enhanced effectiveness in introducing at least 5 mg large single dose of agent into pulmonary tract.

23 cl, 20 dwg, 11 tbl

FIELD: medicine.

SUBSTANCE: method involves acidifying and/or alkalinized by buffering and/or controlling pH to provide nicotine tmax in arterial subject blood in short time after introduction. Aerosol atomizing is preferentially done into oral cavity for following distribution in lungs. Method for preparing the composition, system for achieving smoking desire reduction and/or satisfaction feeling without smoking is also suggested.

EFFECT: enhanced effectiveness in introducing nicotine via lungs; avoided harmful actions caused by smoking.

24 cl

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: claimed composition represents emulsion from phospholipids in form of liposome with average particle size of 0.2-0.4 mum having membranes with integrated dihydroquercetin flavonoid and wheat germ oil, containing hydrophobic antioxidants such as tocopherols (Vitamin E) and carothenoids. Emulsion water phase contains sodium chloride, water soluble antioxidants such as ascorbic acid (Vitamin C), N-acetyl L-cysteine and sodium benzoate.

EFFECT: effective composition for inhalation with prolonged storage time.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves administering dry inhalation with essential oils in closed room. Eucalyptus and fir oils are used as essential oils. Inhalation is carried out in three stages. The first stage involves applying essential oil of eucalyptus 8 days long with 5 days long inhalation period, 3 days long pause and 3 days long inhalation period. Room saturation with applying essential oil of eucalyptus is started with 5 min a day adding 5 min every following day bringing total inhalation time to 40 min at the eighth day. Eucalyptus oil is applied at a dose of 6 drops per 15 m2. The second stage involves carrying out dry inhalation with two types of essential oils adding inhalation with fir oil. Two days combined inhalation is carried out and then 2 days is pause and 5 days of combined inhalation. Room saturation with fir oil is started with 5 min a day adding 5 min every following day bringing total inhalation time to 35 min at the seventh day. Room saturation with eucalyptus oil is started with 35 min a day subtracting 5 min every following day bringing total inhalation time to 5 min at the seventh day. Saturation with fir oil starts immediately after eucalyptus oil bringing total inhalation time to 40 min per day. Fir oil is used in the amount of 3 drops per 15 m2. The third stage involves carrying out dry inhalation with fir oil only 5 days long. Room saturation with fir oil is started with 40 min a day subtracting 5 min every following day bringing total inhalation time to 20 min at the fifth day.

EFFECT: optimum dose for treating children; improved individual tolerance.

1 dwg, 2 tbl

Up!